Sarepta Therapeutics (NASDAQ:SRPT) Hits New 1-Year Low – What’s Next?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT)’s share price hit a new 52-week low on Monday . The company traded as low as $96.75 and last traded at $97.53, with a volume of 357 shares traded. The stock had previously closed at $97.19.

Wall Street Analysts Forecast Growth

SRPT has been the subject of a number of analyst reports. Needham & Company LLC reiterated a “buy” rating and set a $202.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, February 27th. StockNews.com lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. Royal Bank of Canada cut their target price on shares of Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating for the company in a research report on Thursday, February 27th. Piper Sandler cut their price target on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a research report on Wednesday, November 27th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on shares of Sarepta Therapeutics in a research note on Tuesday, February 11th. They issued a “hold” rating and a $136.00 price target for the company. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Sarepta Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $170.41.

Sarepta Therapeutics Stock Up 0.9 %

The firm’s 50-day moving average price is $111.73 and its two-hundred day moving average price is $119.82. The firm has a market cap of $9.52 billion, a PE ratio of 78.09 and a beta of 0.79. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84.

Insider Buying and Selling at Sarepta Therapeutics

In other news, Director Claude Nicaise sold 2,491 shares of the stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the transaction, the director now directly owns 27,812 shares in the company, valued at $2,771,187.68. This represents a 8.22 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 7.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Sarepta Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in Sarepta Therapeutics by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 9,085,456 shares of the biotechnology company’s stock worth $1,104,701,000 after acquiring an additional 117,904 shares during the period. Capital International Investors grew its stake in shares of Sarepta Therapeutics by 38.9% in the 4th quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company’s stock valued at $1,057,482,000 after buying an additional 2,437,855 shares in the last quarter. Janus Henderson Group PLC grew its stake in shares of Sarepta Therapeutics by 14.2% in the 3rd quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock valued at $544,408,000 after buying an additional 543,143 shares in the last quarter. Farallon Capital Management LLC boosted its position in Sarepta Therapeutics by 11.1% during the fourth quarter. Farallon Capital Management LLC now owns 2,865,100 shares of the biotechnology company’s stock worth $348,368,000 after purchasing an additional 285,100 shares during the period. Finally, Wellington Management Group LLP boosted its position in Sarepta Therapeutics by 32.3% during the third quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock worth $340,527,000 after purchasing an additional 665,087 shares during the period. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.